BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus price objective of $8.50 for the company and are predicting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also assigned BrainStorm Cell Therapeutics an industry rank of 111 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $5.00 target price on BrainStorm Cell Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th.
Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) opened at 2.40 on Friday. BrainStorm Cell Therapeutics has a one year low of $1.90 and a one year high of $3.87. The company has a 50-day moving average of $2.43 and a 200 day moving average of $2.43. The stock’s market cap is $44.77 million.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.13. On average, analysts predict that BrainStorm Cell Therapeutics will post ($0.34) earnings per share for the current year.
A hedge fund recently raised its stake in BrainStorm Cell Therapeutics stock. Vanguard Group Inc. boosted its position in BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 491,867 shares of the biotechnology company’s stock after buying an additional 6,200 shares during the period. Vanguard Group Inc. owned about 2.64% of BrainStorm Cell Therapeutics worth $1,186,000 at the end of the most recent reporting period. 8.74% of the stock is owned by institutional investors.
About BrainStorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BrainStorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainStorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.